GSK confirms deal to supply 300 million COVID-19 vaccine doses to the EU

GlaxoSmithKline has confirmed a new COVID-19 vaccine supply deal to deliver 300 million doses of its candidate to the European Commission.

On the condition that the vaccine secures regulatory approval, all European Union member states will be eligible to access the therapy.

Under the terms of the agreement, the EU will also have the option to provide a proportion of the reserved doses to low and middle-income nations. The EU has also committed upfront funding to support the scale-up of the project.

The confirmation of the partnership follows an initial announcement on 31 July.

The candidate combines Sanofi’s Influenza vaccine platform with GSK’s adjuvant technology. It is currently undergoing Phase 1/2 trials, with a Phase 3 study planned for the end of the year.

“Both companies have significant research and development and manufacturing capability in Europe and are already working hard to scale up production across our networks,” Roger Connor, President of GSK vaccines, said of the deal. “This announcement from the European Commission supports our ongoing efforts.”

Matt Fellows